Research Guide

Retatrutide (LY3437943): Triple-Agonist Mechanism & TRIUMPH Trial Data

Retatrutide is the first peptide engineered to engage GLP-1, GIP, and glucagon receptors with a single molecule. This research guide summarises the pharmacology, published Phase 2 outcomes, dosing schedules used in trials, and where Retatrutide fits relative to Semaglutide and Tirzepatide — for in-vitro laboratory research only.

Bottom line: Retatrutide (CAS 2381089-83-2) is a 39-amino-acid investigational triple agonist developed by Eli Lilly. In Phase 2 obesity trials (NEJM 2023) the 12 mg weekly arm produced -24.2% mean weight change at 48 weeks — the highest reported for any incretin compound in trials of comparable design. Its glucagon-receptor arm adds direct energy expenditure and hepatic fat oxidation that neither Semaglutide (GLP-1 only) nor Tirzepatide (GLP-1 + GIP) provides. Retatrutide remains in the Phase 3 TRIUMPH program and is not FDA approved; any acquisition is strictly for in-vitro research use.

Triple-Receptor Mechanism

Retatrutide's molecular design layers three distinct metabolic mechanisms onto a single weekly dose. Each receptor contributes effects that complement, rather than duplicate, the others.

GLP-1

Reduced appetite via hypothalamic signalling, delayed gastric emptying, and glucose-dependent insulin secretion.

GIP

Insulin sensitisation, adipose tissue remodelling, and amplification of GLP-1 effects through receptor crosstalk.

Glucagon

Elevated basal energy expenditure, hepatic fat oxidation, and thermogenesis — the arm unique to triple agonists.

The TRIUMPH Phase 3 Program

Trial	Population	Primary Focus
TRIUMPH-1	Adults with obesity, no T2D	Weight change at 72 weeks
TRIUMPH-2	Adults with obesity + T2D	Weight + HbA1c outcomes
TRIUMPH-3	Adults with obesity + established CV disease	Major adverse cardiovascular events (MACE)
TRIUMPH-4	Adults with obesity + knee OA / weight-related comorbidities	Weight + comorbidity composite

Outcomes summarised here are drawn from publicly registered protocols and published Phase 2 readouts. Phase 3 readouts will be added to this guide as results are peer-reviewed.

📊 Phase 2 Headline Numbers

-24.2% mean weight change at 48 weeks on 12 mg weekly (Jastreboff et al., NEJM 2023) — placebo -2.1%.
~85% mean reduction in hepatic fat fraction in MASLD/NAFLD Phase 2 imaging substudy on the highest dose arm.
Dose–response across 1, 4, 8, and 12 mg arms with no plateau observed at 12 mg through 48 weeks.
Step titration (2 → 4 → 8 → 12 mg over 12 weeks) used to reduce GI tolerability events.

Receptor Coverage vs Tirzepatide & Semaglutide

Compound	GLP-1	GIP	Glucagon	Peak Phase 2/3 Weight Loss
Semaglutide	✓	—	—	~16.9% (STEP 1)
Tirzepatide	✓	✓	—	~22.5% (SURMOUNT-1)
Retatrutide	✓	✓	✓	~24.2% Phase 2 (48 wk)

Reported Safety & Tolerability

The Phase 2 safety profile is consistent with the incretin-agonist class. Gastrointestinal events — nausea, diarrhoea, and vomiting — were the most common treatment-emergent events, predominantly mild-to-moderate and concentrated during the titration phase. Modest, dose-related increases in resting heart rate were observed, in line with the glucagon-receptor arm. Phase 3 cardiovascular outcomes data (TRIUMPH-3) will be required before any class-comparative cardiovascular conclusions can be drawn.

Frequently Asked Questions

What makes Retatrutide a triple agonist?

Retatrutide (LY3437943) is a 39-amino-acid peptide engineered to bind and activate three incretin/metabolic receptors simultaneously: GLP-1, GIP, and glucagon. Each receptor contributes a distinct mechanism — appetite suppression (GLP-1), insulin sensitisation and adipose remodelling (GIP), and direct energy expenditure plus hepatic fat oxidation (glucagon). No FDA-approved compound combines all three.

What are the headline TRIUMPH Phase 2 results?

In the Phase 2 obesity study (Jastreboff et al., NEJM 2023), participants on the highest 12 mg weekly dose showed a least-squares mean weight change of -24.2% at 48 weeks vs -2.1% on placebo. A Phase 2 study in MASLD (TRIUMPH-2) reported up to ~85% reduction in liver fat content. These are research outcomes — Retatrutide remains investigational.

Is Retatrutide FDA approved?

No. Retatrutide is in the Phase 3 TRIUMPH clinical development program (TRIUMPH-1 obesity, TRIUMPH-3 cardiovascular outcomes, TRIUMPH-4 obesity with weight-related comorbidities). Any laboratory acquisition is for in-vitro research use only and not for human consumption.

How does Retatrutide compare to Tirzepatide and Semaglutide on receptor coverage?

Semaglutide is a GLP-1 mono-agonist. Tirzepatide adds GIP (dual). Retatrutide adds glucagon on top of GLP-1 + GIP (triple). The glucagon arm is what distinguishes Retatrutide — it is the only one of the three that directly raises basal energy expenditure rather than only reducing caloric intake.

What dosing schedule is used in published Retatrutide trials?

Trials used once-weekly subcutaneous administration with a step-titration schedule (typically 2 mg → 4 mg → 8 mg → 12 mg over 12 weeks) to mitigate GI tolerability events. Pharmacokinetic analyses report a half-life consistent with weekly dosing (~6 days).

What safety signals were observed in Phase 2?

The Phase 2 obesity trial reported a class-typical GI profile (nausea, diarrhoea, vomiting) as the dominant treatment-emergent events, generally mild-to-moderate and concentrated during titration. Small dose-related increases in heart rate were observed. No new safety signals beyond the incretin-agonist class have been published as of the Phase 2 readouts.

For research use only. Retatrutide is an investigational compound in Phase 3 clinical trials and is not approved for human consumption by the FDA or any other regulatory body. All material acquired from PeptidesDirect is supplied strictly for in-vitro laboratory research conducted by qualified professionals.

Retatrutide — Research Compound

5 mg vial · ≥99% HPLC purity · CertikLabs verified

View Product →